Trial · NCT01429090
Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution
NCT01429090, Phase 1, Completed, University Medicine Greifswald
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution. Trials, record NCT01429090. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01429090
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution
- NCT number
- NCT01429090
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 12 participants, actual
- Lead sponsor
- University Medicine Greifswald
- Conditions
- Neurogenic Bladder
- Interventions
- blood sampling, Vagantin®, methantheline solution, Measurement of salivation, Measurement of accommodation, Pupillometry
- First posted
- 2011-09-05
- Last updated
- 2011-09-05
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | area under the curve (AUC0-∞) | 0-16 h plasma concentration-time profile of methantheline after single oral administration | AUC0-∞ was assessed by the trapezoidal formula up to the last sampling time with a concentration above the limit of quantitation (AUC0-), and was extrapolated to infinity using standard techniques |
| Primary | maximal plasma concentration (Cmax) | 0-16 h plasma concentration-time profile of methantheline after single oral administration | Cmax was obtained directly from the measured concentration-time curves |
| Secondary | time of maximal plasma concentration (tmax) | 0-16 h plasma concentration-time profile of methantheline after single oral administration | tmax was obtained directly from the measured concentration-time curves |
| Secondary | terminal half-life (t½) | 0-16 h plasma concentration-time profile of methantheline after single oral administration | Half-life (t½) was evaluated by non-linear regression of the terminal slope |
| Secondary | volume of salivary gland secretion | before and 0, 0.5, 1, 2, 3, 4, 6, 8, 12 hours after administration of study medication | Volume of salivary gland secretion will be measured by chewing a 5 x 5 cm piece of PARAFILM "M"® (American Can Company, UK) for 5 min. Saliva will be collected in glass tubes the volume of which will be measured be weighing |
| Secondary | Measurement of accommodation | before and 0, 1, 2, 3, 4, 6, 8, 12 hours after administration of study medication | Accommodation will be measured with the optometer according to Schober (Velhagen 1972) |
| Secondary | Pupil function | before and 0, 1, 2, 3, 4, 6, 8, 12 hours after administration of study medication | Pupil function will be assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data will be obtained: pupil diameter, response to defined flash stimuli |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22527350 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01429090
GET https://conductscience.org/api/trials/v1/NCT01429090/registered